Novo-partnered microcap biotech forced to halt PhIII enrollment in Russia and Ukraine as war continues
Russia’s invasion of Ukraine continues to impact the biopharma industry, with a microcap player announcing Monday it will be forced to delay a pivotal study readout.
Though a blip in the grand scheme of things compared to the bombing of residential areas, maternity hospitals and nuclear power plants, Russia’s war is prompting Novo Nordisk partner Aeterna Zentaris to halt Phase III enrollment at Ukrainian and Russian trial sites. After already being delayed by the pandemic, the study will now likely push into 2023 as at least 25% of the expected patients were slated to come from Russia and Ukraine, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.